Merck & Co. (MRK) : Cutler Capital Management reduced its stake in Merck & Co. by 0.39% during the most recent quarter end. The investment management company now holds a total of 119,705 shares of Merck & Co. which is valued at $6,564,622 after selling 474 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Apr 26, 2016.Merck & Co. makes up approximately 2.96% of Cutler Capital Management’s portfolio.
Merck & Co. opened for trading at $54.85 and hit $55.36 on the upside on Monday, eventually ending the session at $55.3, with a gain of 0.84% or 0.46 points. The heightened volatility saw the trading volume jump to 96,78,915 shares. Company has a market cap of $153,472 M.
Other Hedge Funds, Including , Texas Permanent School Fund reduced its stake in MRK by selling 29,701 shares or 3.01% in the most recent quarter. The Hedge Fund company now holds 957,832 shares of MRK which is valued at $52,527,507. Merck & Co. makes up approx 0.66% of Texas Permanent School Fund’s portfolio.Louisiana State Employees Retirement System reduced its stake in MRK by selling 10,100 shares or 5.16% in the most recent quarter. The Hedge Fund company now holds 185,600 shares of MRK which is valued at $10,178,304. Merck & Co. makes up approx 0.53% of Louisiana State Employees Retirement System’s portfolio.Integrated Wealth Management reduced its stake in MRK by selling 1,059 shares or 3.44% in the most recent quarter. The Hedge Fund company now holds 29,710 shares of MRK which is valued at $1,685,745. Merck & Co. makes up approx 0.70% of Integrated Wealth Management’s portfolio.Bkd Wealth Advisors reduced its stake in MRK by selling 866 shares or 2.82% in the most recent quarter. The Hedge Fund company now holds 29,789 shares of MRK which is valued at $1,672,354. Merck & Co. makes up approx 0.26% of Bkd Wealth Advisors’s portfolio.Blue Bell Private Wealth Management boosted its stake in MRK in the latest quarter, The investment management firm added 1,786 additional shares and now holds a total of 3,971 shares of Merck & Co. which is valued at $222,932. Merck & Co. makes up approx 0.15% of Blue Bell Private Wealth Management’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.